France · Source-listed medicine information
France / CIS 66743613
VAMINOLACT, solution pour perfusion en flacon
solution pour perfusion · intraveineuse
Source data retrieved: 2026-09-17. Clinical review is not yet available.
Product identity
At a glance
- Authorisation holder
- FRESENIUS KABI FRANCE
- Authorisation status
- Autorisation active
- Market status
- Commercialisée
- Country
- France
- Source reference
- CIS 66743613
Reported market status does not confirm current pharmacy stock.
From the official composition record
Ingredients & strength
Source entries are shown individually. An active substance (SA) and its reference moiety (FT) may describe the same ingredient; do not add their strengths together.
| Ingredient | Strength / reference | Source role |
|---|---|---|
| ASPARTIQUE (ACIDE)solution | 4,1 g1000 ml | SAGroup 3 |
| ALANINEsolution | 6,3 g1000 ml | SAGroup 1 |
| CYSTÉINEsolution | qsp 1 g de mélange L-cystéine / L-cystine1000 ml | SAGroup 4 |
| HISTIDINEsolution | 2,1 g1000 ml | SAGroup 8 |
| ISOLEUCINEsolution | 3,1 g1000 ml | SAGroup 9 |
| LEUCINEsolution | 7 g1000 ml | SAGroup 10 |
| LYSINEsolution | 5,6 g1000 ml | SAGroup 11 |
| PHÉNYLALANINEsolution | 2,7 g1000 ml | SAGroup 13 |
| SÉRINEsolution | 3,8 g1000 ml | SAGroup 15 |
| THRÉONINEsolution | 3,6 g1000 ml | SAGroup 17 |
| TRYPTOPHANE Lsolution | 1,4 g1000 ml | SAGroup 18 |
| VALINEsolution | 3,6 g1000 ml | SAGroup 20 |
| GLYCINEsolution | 2,1 g1000 ml | SAGroup 7 |
| ACIDE L-GLUTAMIQUEsolution | 7,1 g1000 ml | SAGroup 6 |
| ARGININEsolution | 4,1 g1000 ml | SAGroup 2 |
| TAURINEsolution | 0,3 g1000 ml | SAGroup 16 |
| MÉTHIONINEsolution | 1,3 g1000 ml | SAGroup 12 |
| PROLINEsolution | 5,6 g1000 ml | SAGroup 14 |
| TYROSINEsolution | 0,5 g1000 ml | SAGroup 19 |
| CYSTINEsolution | qsp 1 g de mélange L-cystéine / L-cystine1000 ml | SAGroup 5 |
Pack references
Presentations (3)
CIP13 3400932997619
Présentation active · Déclaration de commercialisationCIP13 3400932997848
Présentation active · Déclaration de commercialisationCIP13 3400932998098
Présentation active · Déclaration de commercialisationFrom the French medicines authority
Official documents
The official product entry provides access to the patient leaflet and professional product information when available. Documents are in French and availability varies by medicine.
Open the official product entryBDPM · CIS 66743613 · Opens in a new tabCheck the medicine name, strength and form against your pack. The authority’s current documents may be newer than the catalogue snapshot shown here.
Where this information comes from
Sources & dates
Base de données publique des médicaments (BDPM), France. Retrieval dates record when we obtained the source files; they are not clinical review dates or a guarantee of current stock.
| Source file | Retrieved | Source file modified |
|---|---|---|
| fr_products.txt | Not supplied | |
| fr_composition.txt | Not supplied | |
| fr_packs.txt | Not supplied |
Directory source checks cover the factual catalogue record.Molindra clinical guidance has not yet been reviewed or published for this medicine.
Our sources and review process →